PHARMACOKINETICS-PHARMACODYNAMICS OF
ANTICANCER DRUGS: RESISTANCES AND SYNERGIES

PARIS, CORDELIERS RESEARCH CENTRE, DECEMBER 18-19, 2008: PROGRAMME
A list of speakers and topics of their talks

  1. Annabelle Ballesta (INRIA, France) "A Combined Biological and Mathematical Approach for Modeling the PK-PD of the Anticancer Drug Irinotecan - Focus on Acquired Resistance and Circadian Rhythms at the Cell Population Scale" [Abstract] [Presentation in pdf]

  2. Justine Bodin (Lyon, France) on 5FU PK-PD modelling from mathematics to the clinic [Abstract]

  3. Jean Clairambault (INRIA, France) "Towards optimisation of cancer therapeutics by taking into account patient-specific constraints: mathematical models for individualised medicine" [Abstract] [Presentation in pdf]

  4. Dinesh DeAlwis (Eli Lilly, UK) "Exploring the Potential of PK/PD in Early Phase Oncology Drug Development" [Abstract]

  5. Albert Goldbeter (ULB, Brussels, Belgium) "Using an automaton model for the cell cycle to probe temporal patterns of drug administration in cancer chronotherapy" [Abstract] [Web page]

  6. Peter Hinow (U. Minnesota, Minneapolis, MN) "A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase" [Abstract] [Presentation in pdf]

  7. Peter Kim (U. Utah, Salt Lake City, UT) "Potential sources of drug resistance during Imatinib treatment of CML" [Abstract] [Presentation in pdf]

  8. Francis Lévi (Villejuif, France) "Circadian clock induction or disruption in cancer therapy" [Abstract] [Presentation in pdf]

  9. Pierre Magal (Le Havre, France) "Modelling P-gp transfer and acquired multi-drug resistance in tumour cells" [Abstract]

  10. Jean-Pierre Marie (Paris, France) "Drug resistance induced by ABC-transporter proteins" [Abstract] [Presentation in pdf]

  11. Inès Paule (Lyon, France) "Individual dose adaptation of capecitabine for reduction of severe hand-and-foot syndrome" [Abstract] [Presentation in pdf]

  12. Benjamin Ribba (Lyon, France) "Mechanistic PK/PD models to reveal synergy between anti-angiogenesis drugs and chemotherapy" [Abstract]

  13. Jeannette Soria (Paris, France) "Micro-environment and drug resistance in leukemia and ovarian cancer" [Abstract]

  14. Maciej Swat (Simcyp, UK) "Modelling of PK-PD and drug-drug interaction (synergy /antagonism /additivity) with examples of anti-cancer and anti-inflammatory drug combinations" [Abstract]

  15. Andrzej Swierniak (Gliwice, Poland) "Direct and indirect control of drug resistant cancer populations" [Abstract] [Presentation in pdf]

  16. Jack Tuszynski (U. Alberta, Edmonton, Alberta, Canada) "Computational cancer chemotherapy drug design and laboratory validation" [Abstract]

  17. Vladimir Vainstein (Hadassah, Jerusalem, Israel) "Physiologically-based PK/PD of targeted drug delivery by monoclonal antibodies" [Abstract] [Web page]

  18. Alissa Weaver (U. Vanderbilt, Nashville, TN) "Modulation of drug response and selection of clonal populations by microenvironment constraints" [Abstract] [Web page]

Back to the workshop homepage